🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

469 results for “Astra” Clear

  1. Tozorakimab-placebo, Tozorakimab, SALBUTAMOL

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  2. Trastuzumab Deruxtecan

    AstraZeneca

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  3. Trastuzumab Deruxtecan

    AstraZeneca

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. Trastuzumab deruxtecan

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  5. Trastuzumab deruxtecan

    AstraZeneca

    Breast Cancer; HER2-positive; Metastatic

    phase 3 small molecule active

    1 trial

  6. Tremelimumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  7. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  8. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  9. Verzenios 150 mg film-coated tablets, EXEMESTANE, IBRANCE 75 mg film-coated tablets, Verzenios 100 mg film-coated tablets, FULVESTRANT, LETROZOLE, Camizestrant, IBRANCE 100 mg film-coated tablets, Saruparib, Verzenios 50 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, ANASTROZOLE

    AstraZeneca AB

    Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  10. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  11. Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  12. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  13. Xtandi - 40 mg soft capsules, Xtandi - 40 mg soft capsules, TALAZOPARIB, Xtandi 40 mg soft capsules, TALAZOPARIB, Xtandi - 40 mg soft capsules, Talazoparib placebo

    Pfizer Australia Pty Ltd

    Metastatic Castration-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  14. ZYTIGA 250 mg tablets, Placebo to match (PTM) AZD5305 film-coated tablets, Saruparib, ZYTIGA 500 mg film-coated tablets

    AstraZeneca AB

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  15. ZYTIGA 250 mg tablets, ZYTIGA 500 mg film-coated tablets, Apalutamide placebo, JNJ-56021927, PREDNISONE, -

    Lacuna Pharma Pty Ltd

    Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  16. balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Heart Failure and Impaired Kidney Function

    phase 3 small molecule active

    1 trial

  17. budesonide/formoterol 'as needed' + budesonide placebo bid

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  18. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  19. custirsen sodium

    Teva Pharma GmbH

    Castrate-Resistant Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  20. exenatide once weekly

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  21. volrustomig

    AstraZeneca

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  22. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  23. ​Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources